|
|||
|
DRUGS & SUPPLEMENTS
|
Q Pin
How is the drug helping you? |
Q Pin uses
Pharmacological action
Q Pin is an antipsychotic drug. This medication exhibits a high affinity for serotonin 5HT2-receptors compared with dopamine D1- and D2-receptors in the brain. Also Q Pin has a high affinity for histamine and alpha1-receptors and a less pronounced - to the alpha2-receptors. This drug has no affinity for the m-cholinergic receptors and benzodiazepine receptors.
Q Pin in the dose effectively blocking dopamine D2-receptors causing only weak catalepsy. Q Pin selectively reduces the activity of mesolimbic dopamine neurons in A10-compared with A9-nigrostriatalnymi neurons involved in motor function. This medicine does not cause long raise prolactin levels.
In accordance with the results of positron emission tomography effect of Q Pin on serotonin 5HT2- and dopamine D2-receptors can be extended to 12 h.
Pharmacokinetics
Q Pin after oral administration is well absorbed from the gastrointestinal tract. Ingestion did not significantly affect the bioavailability of Q Pin.
The pharmacokinetics of Q Pin is linear.
Plasma protein binding is about 83%.
This medication subjected to intensive metabolism. In "in vitro" studies there was revealed that a key enzyme metabolism of Q Pin is CYP3A4.
The main metabolites detected in blood plasma does not possess a pronounced pharmacological activity.
T1/2 is about 7 hours. Less than 5% of Q Pin excreted unchanged in the kidneys or the intestines. Approximately 73% of metabolites excreted by the kidneys and 21% through the intestines.
The average clearance of Q Pin in elderly patients is 30-50% lower than observed in patients aged 18 to 65 years.
The average plasma clearance of Q Pin was approximately less than 25% in patients with severely impaired renal function (creatinine clearance less than 30 ml / min / 1.73 m2) and in patients with liver disease (alcoholic cirrhosis in the stage of compensation) but the individual clearance levels were within the limits of the healthy people.
The pharmacokinetics of Q Pin do not depend on gender.
Why is Q Pin prescribed?
Acute and chronic psychosis.
Dosage and administration
When use for adult the starting dose is 50 mg for elderly patients is 25 mg / day. Then gradually increase the dose according to the scheme. Depending on the clinical effect and individual sensitivity of the effective therapeutic dose can be 150-750 mg / day.
Patients with impaired liver function and / or renal starting dose is 25 mg / day. The daily dose increase should be 25-50 mg to achieve an optimal effect.
Q Pin side effects, adverse reactions
CNS: headache, drowsiness, dizziness, anxiety.
Cardio-vascular system: orthostatic hypotension, tachycardia, hypertension.
Digestive system: constipation, dry mouth, dyspepsia, diarrhea, transient elevation of liver enzymes, abdominal pain.
Blood: asymptomatic leukopenia and / or neutropenia, rarely - eosinophilia.
Musculoskeletal system: myalgia.
With the respiratory system: rhinitis.
Dermatological reactions: skin rash, dry skin.
Organ of hearing: ear pain.
Genitourinary system: urinary tract infection.
Endocrine system: a slight elevation of serum cholesterol and triglycerides, a small dose-related reversible reduction in thyroid hormone levels (particularly total and free T4).
Other: asthenia, pain, weight gain, fever, chest pain.
Q Pin contraindications
Hypersensitivity to Q Pin.
Using during pregnancy and breastfeeding
During pregnancy and lactation Q Pin use is possible in cases where the expected benefit to the mother justifies the potential risk to the fetus. It is unknown whether the allocated Q Pin in breast milk.
In experimental studies in animals it was showed no mutagenic and clastogene of Q Pin. Found no effect of Q Pin on fertility, but you can not directly transfer the data obtained in person, because there are specific differences in hormonal control of reproduction. Category effects on the fetus by FDA is C.
Special instructions
Q Pin used with careful in patients with cardiovascular diseases and other conditions associated with the risk of hypotension, especially at the beginning of treatment and the elderly, and specifying a history of seizures convulsions.
Q Pin undergoes active metabolism in the liver. Patients with impaired liver and renal clearance of Q Pin is reduced by approximately 25%. Thats why Q Pin should be used with caution in patients with impaired liver function and / or kidneys.
This medication with careful use concurrently with drugs that prolong the interval QT (especially the elderly) with drugs that provide a depressing effect on the CNS, as well as ethanol; with potent inhibitors of isoenzyme CYP3A4 (including those with ketoconazole, erythromycin).
With the development of NMS during treatment with Q Pin it should be revoked and appropriate treatment.
With prolonged use there is a risk of tardive dyskinesia. In such cases it is necessary to reduce the dose of Q Pin or cancel it.
Q Pin used with caution in combination with other drugs that affect the activity of the CNS, as well as with ethanol.
Q Pin may cause drowsiness, so patients are not encouraged to perform tasks associated with the need to focus and speed of psychomotor reactions (including driving vehicles).
Q Pin drug interactions
Simultaneous administration of Q Pin with:
Q Pin in case of emergency / overdose
Symptoms: drowsiness, sedation, tachycardia, hypotension.
Treatment: symptomatic; restoration and control of upper airway patency, maintenance of adequate oxygenation and ventilation, monitoring and maintenance of the cardiovascular system.
Q Pin pharmaceutical active ingredients containing related brand and generic drugs:
Q Pin available forms, composition, doses:
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.